Emcure launched first generic version of Eisai Pharmaceutical’s Halaven (Eribulin) in India

Emcure Pharmaceuticals announced the launch of first generic version of Eisai Pharmaceutical’s Halaven (Eribulin) for the treatment of metastatic breast cancer (MBC). Emcure will be marketing the drug under brand name ‘Eribilin’, with an aim to offer high-quality and cost-effective treatment option to breast cancer patients in India. Emcure’s Eribilin has been approved by DCG(I) to be marketed in India.

The product is a generic version of Eisai Pharmaceutical’s cancer drug sold under the brand name, Halaven, Emcure Pharmaceuticals said in a statement.

“Breast cancer is the most common type of cancer affecting women in India and its incidence is on the rise. Currently available treatment for triple negative breast cancer in India is out of reach of most patients due to its high cost,” Emcure Pharmaceuticals Business Strategy & Specialty Business President Sainath Iyer said.

Emcure’s Eribilin will be available at a reasonable cost to the patients in India. It will be approximately 40 per cent less than the innovator brand, Emcure Pharmaceuticals said.